A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
Condition: CancerInterventions: Drug: Trametinib 0.5 mg; Drug: Trametinib 2 mg; Drug: ORTHO-NOVUM® tablet 1/35; Drug: PlaceboSponsor: GlaxoSmithKlineNot yet recruiting - verified February 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials